Antiphospholipid antibodies (present in the serum of patients with APS) are known to induce platelet activation and the production of procoagulants such as von Willebrand factor, thereby ...

U.K.-based Epsilogen has bought Boston biotech TigaTx with the aim of creating “the world’s leading pan-isotype cancer ...

UK biotech Epsilogen has acquired US-based antibody developer TigaTx in a deal that collates work from the two companies’ ...

The combined company will clinically advance Epsilogen's MOv18 IgE antibody in ovarian cancer and TigaTx's anti-EGFR IgA antibody.

With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.